| Methods |
4‐week placebo run‐in; inclusion criteria= sitting DBP 95‐110 mm Hg after run‐in; 12‐week total double‐blind treatment, titrated to response at 4 weeks |
| Participants |
Enalapril 10 mg: n=321(188 males,133 females); mean age=52.4(10.2) years; baseline sitting SBP=158.0(15.4) mm Hg, DBP=100.9(4.6) mm Hg;
Placebo: n=304(165 males,135 females); mean age=51.0(10.7) years; baseline SBP=157.2(15.3) mm Hg, DBP=101.0(4.4) mm Hg |
| Interventions |
Enalapril 10 mg once daily;
Placebo |
| Outcomes |
Mean change from baseline in trough sitting SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
Used week 4 BP data only; BP change and SD of change reported, endpoint BP and SD not reported; BP data from Figure I, p. 917; Jadad score=3; funding source= not reported |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
